Literature DB >> 29730837

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

François-Xavier Nouhaud1, Jean-Christophe Bernhard2, Pierre Bigot3, Zine-Eddine Khene4, François Audenet5, Herve Lang6, Sebastien Bergerat6, Guillaume Fraisse5, Nicolas Grenier7, François Cornelis7, Cosmina Nedelcu8, Sofiane Béjar9, Gaëlle Fromont-Hankard10, Yves Allory11, Véronique Lindner12, Virginie Verkarre13, Laurent Daniel14, Mokrane Yacoub15, Jean-Michel Correas16, Arnaud Méjean5, Nathalie Rioux-Leclercq17, Karim Bensalah4.   

Abstract

PURPOSE: To evaluate and compare pathological characteristics of renal cysts Bosniak IIF, III and IV in light of recent histological classification. PATIENTS AND METHODS: The French research network for kidney cancer UroCCR conducted a multicentre study on patients treated surgically for a renal cyst between 2007 and 2016. Independent radiological and centralized pathological reviews were performed for every patient. Pathological characteristics were compared to the Bosniak classification.
RESULTS: Of a total 216 patients included, 175 (81.0%) tumours (90.9% of Bosniak IV, 69.8% of Bosniak III) were malignant or had a low malignant potential, with 60% of clear cell renal cell carcinoma (CCRCC), 24% of papillary RCC (PRCC) and 6.9% of multilocular cystic renal tumour of low malignant potential (MCRTLMP). Malignancies were mostly of low pT stage (86.4% of pT1-2), and low ISUP grade (68.0% of 1-2). Bosniak III cysts had a lower rate of CCRCC (46.7 vs. 67.3%), higher rate of PRCC (30 vs. 20.9%) and MCRTLMP (18.3 vs. 0.9%) compared to Bosniak IV (p < 0.001). Low-malignant potential lesions were less likely Bosniak IV and pT3-4 stage was more frequent in Bosniak IV vs. III (15.7 vs. 3.5%; p = 0.04). There were two recurrences (1.1%) and no cancer-related death occurred during follow-up.
CONCLUSION: These results confirmed that cystic renal malignancies have excellent prognosis. Bosniak III cysts had a low malignant potential, which suggests surveillance could be an option for these lesions.

Entities:  

Keywords:  Bosniak classification; Computed tomography; Histology; Low malignant potential; Renal cell carcinoma; Renal cysts

Mesh:

Year:  2018        PMID: 29730837     DOI: 10.1007/s00345-018-2307-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

1.  Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.

Authors:  Thu Tran; Carol L Jones; Sean R Williamson; John N Eble; David J Grignon; Shaobo Zhang; Mingsheng Wang; Lee Ann Baldridge; Lisha Wang; Rodolfo Montironi; Marina Scarpelli; Puay-Hoon Tan; Novae B Simper; Eva Comperat; Liang Cheng
Journal:  Histopathology       Date:  2015-10-21       Impact factor: 5.087

2.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.

Authors:  Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

Review 3.  An update of the Bosniak renal cyst classification system.

Authors:  Gary M Israel; Morton A Bosniak
Journal:  Urology       Date:  2005-09       Impact factor: 2.649

4.  Pathological characteristics and radiographic correlates of complex renal cysts.

Authors:  Adam C Reese; Pamela T Johnson; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf; Elliot K Fishman; George J Netto; Christian P Pavlovich
Journal:  Urol Oncol       Date:  2014-07-09       Impact factor: 3.498

5.  [CCAFU french national guidelines 2016-2018 on renal cancer].

Authors:  K Bensalah; L Albiges; J-C Bernhard; P Bigot; T Bodin; R Boissier; J-M Corréas; P Gimel; J-A Long; F-X Nouhaud; I Ouzaïd; P Paparel; N Rioux-Leclercq; A Méjean
Journal:  Prog Urol       Date:  2016-11       Impact factor: 0.915

Review 6.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

7.  The current radiological approach to renal cysts.

Authors:  M A Bosniak
Journal:  Radiology       Date:  1986-01       Impact factor: 11.105

8.  Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.

Authors:  Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

9.  Complex cystic renal masses: characterization with contrast-enhanced US.

Authors:  Giorgio Ascenti; Silvio Mazziotti; Giovanni Zimbaro; Nicola Settineri; Carlo Magno; Darwin Melloni; Rosario Caruso; Emanuele Scribano
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

10.  Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.

Authors:  Stephen D W Beck; Manish I Patel; Mark E Snyder; Michael W Kattan; Robert J Motzer; Victor E Reuter; Paul Russo
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

View more
  2 in total

1.  Contrast-enhanced Ultrasound (CEUS) vs contrast-enhanced computed tomography for multilocular cystic renal neoplasm of low malignant potential: A retrospective analysis for diagnostic performance study.

Authors:  Kun Shan; A Bu DU Li Ai Ze Zi Ha Li Fu; Ningning Liu; Qiliang Cai; Qingfeng Fu; Leyi Liu; Xiaoyu Sun; Zhihong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

2.  [Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19].

Authors:  A Méjean; M Rouprêt; F Rozet; K Bensalah; T Murez; X Game; X Rebillard; R Mallet; A Faix; P Mongiat-Artus; G Fournier; Y Neuzillet
Journal:  Prog Urol       Date:  2020-03-30       Impact factor: 0.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.